James S. Fraser, Steven Edgar, L. Naomi Handly, Sriram Kosuri, John D. Chodera, Mark Murcko, W. Patrick Walters
Drug discovery often fails due to unpredictable ADMET issues, which account for 30% of clinical setbacks. Conventional methods lack the atomistic detail needed to navigate the "Avoid-ome"-a finite set of proteins acting as "anti-targets". OpenADMET is an open-science initiative addressing this by creating pre-competitive, mechanistic datasets. Using high-throughput structural biology, active learning, and community challenges, it builds generalizable models grounded in structural "ground truth". By directly studying the Avoid-ome, OpenADMET facilitates an era of rational, multi-parameter drug design.